# Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)

> **NCT00174772** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 72 (actual)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy
- **DRUG:** docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin

## Key facts

- **NCT ID:** NCT00174772
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2010-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00174772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00174772, "Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00174772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*